World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
92
Citations
39365
World Ranking
11141
National Ranking
1057

Overview

Oliver G. Ottmann is affiliated with Cardiff University in the United Kingdom. Their research spans multiple areas within medicine and biochemistry, genetics, and molecular biology, with a focus on hematology and oncology-related conditions.

Ottmann's scholarly output encompasses numerous publications, including recent papers such as:

  • Unified classification and risk-stratification in Acute Myeloid Leukemia (2022, Nature Communications)
  • Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy (2023, Cell)
  • Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study (2021, Blood)
  • Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study (2021, European Journal of Cancer)
  • Management of ALL in adults: 2024 ELN recommendations from a European expert panel (2024, Blood)

The scientist collaborates frequently with other researchers, including Kimmo Porkka, Norbert Vey, Andrew H. Wei, Andrew M. Brunner, and Steven Knapper.

Ottmann's research has been published predominantly in several key medical and hematology journals, including:

  • Blood (11 publications)
  • Clinical Lymphoma Myeloma & Leukemia (4 publications)
  • Leukemia (3 publications)
  • Annals of Hematology (3 publications)
  • Investigational New Drugs (3 publications)

Main research fields include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Within these fields, Ottmann has contributed to specialized subfields such as:

  • Hematology
  • Molecular Biology
  • Genetics
  • Public Health, Environmental and Occupational Health
  • Oncology

The scientist focuses on topics including:

  • Chronic Myeloid Leukemia Treatments
  • Acute Myeloid Leukemia Research
  • Chronic Lymphocytic Leukemia Research
  • Acute Lymphoblastic Leukemia Research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Lymphoma Diagnosis and Treatment
  • Histone Deacetylase Inhibitors Research

Best Publications

  • Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

    Hagop M Kantarjian;Charles Sawyers;Andreas Hochhaus;Francois Guilhot

  • Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study

    Charles L. Sawyers;Andreas Hochhaus;Eric Feldman;John M. Goldman

  • Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.

    Hagop M Kantarjian;Francis Giles;Lydia Wunderle;Kapil Bhalla

  • Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.

    Moshe Talpaz;Richard T. Silver;Brian J. Druker;John M. Goldman

  • Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

    Max S. Topp;Peter Kufer;Nicola Gökbuget;Mariele Goebeler

  • A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

    Oliver G. Ottmann;Brian J. Druker;Charles L. Sawyers;John M. Goldman

  • A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.

    Walter Fiedler;Hubert Serve;Hartmut Döhner;Michael Schwittay

  • Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis

    Jorge E Cortes;Philippe Rousselot;Dong Wook Kim;Ellen Ritchie

  • Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

    Max S. Topp;Nicola Gökbuget;Gerhard Zugmaier;Evelyn Degenhard

  • Treatment of patients with advanced cancer with the natural killer cell line NK-92

    Torsten Tonn;Torsten Tonn;Dirk Schwabe;Hans G. Klingemann;Sven Becker;Sven Becker

  • Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes

    Felicitas Thol;Sofia Kade;Carola Schlarmann;Patrick Löffeld

  • Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results

    Hagop M. Kantarjian;Francis J. Giles;Kapil N. Bhalla;Javier A. Pinilla-Ibarz

  • Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study.

    Giovanni Martinelli;Nicolas Boissel;Patrice Chevallier;Oliver Ottmann

  • Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph^+ALL)

    Barbara Wassmann;Heike Pfeifer;Nicola Goekbuget;Dietrich W. Beelen

  • Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

    Jorge E. Cortes;Florian H. Heidel;Andrzej Hellmann;Walter Fiedler

  • Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008

    M. Bruggemann;A. Schrauder;T. Raff;H. Pfeifer

  • Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes--a phase I/II trial.

    A Ganser;B Volkers;J Greher;OG Ottmann

  • Demonstration of the Th1 to Th2 cytokine shift during the course of HIV-1 infection using cytoplasmic cytokine detection on single cell level by flow cytometry

    Stefan A. Klein;Jürgen M. Dobmeyer;Thomas S. Dobmeyer;Martine Pape

  • A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia.

    Walter Fiedler;Rolf Mesters;Heike Tinnefeld;Sonja Loges

  • Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Commentary

    John Goldman;Jorge Cortes;Philippe Rousselot;Dong-Wook Kim

Frequent Co-Authors

Dieter Hoelzer
Dieter Hoelzer Goethe University Frankfurt
Arnold Ganser
Arnold Ganser Hannover Medical School
Andreas Hochhaus
Andreas Hochhaus Friedrich Schiller University Jena
Francis J. Giles
Francis J. Giles Northwestern University
Hubert Serve
Hubert Serve Goethe University Frankfurt
Michael Lübbert
Michael Lübbert University of Freiburg
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Jorge E. Cortes
Jorge E. Cortes Augusta University
Michele Baccarani
Michele Baccarani University of Bologna
Richard A. Larson
Richard A. Larson University of Chicago

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Medicine in the USA opens the door to a diverse range of career paths. For students seeking flexible, cost-effective options, several related online degrees can lead to promising roles in healthcare without the time and financial commitment of a traditional medical degree.

A health information technology online degree is ideal if you’re interested in digital health records and data management. This program prepares graduates for critical roles that keep healthcare systems running efficiently.

Those considering administrative roles may want to explore the medical billing and coding cost and its associated programs. These online courses are generally more affordable and provide a streamlined path into healthcare administration.

For students wanting to become advanced clinicians, the most affordable online nurse practitioner programs and affordable online nursing programs can offer flexible study options that lead directly into high-demand nursing careers.

Exploring these alternative online degrees not only broadens your career prospects but also offers accessible pathways into the healthcare field.

Best Scientists Citing Oliver G. Ottmann

Trending Scientists